Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Rheumatoid Arthritis Clinical Trial

Official title:

A Randomized, Controlled, Single-Blind, Exploratory Basket Study to Evaluate the Effects of a DiNaMo™ Component Training in Adults With Chronic Pain-Related Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05573685
• Other study ID #: CT-100-D-002
• Status: Completed
• Phase: N/A
• Start date: October 10, 2022
• Est. completion date: February 6, 2023

Study information

• Verified date: April 2023
• Source: Click Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).

Description:

The Study App (CT-100-002) contains a class of Digital Neuro-activation and Modulation (DiNaMo™) mechanisms of action that are part of the Click Neurobehavioral Intervention (CNI) Platform™. DiNaMo™ provide interactive, software based therapeutic components that may be included in a multimodal treatment for developing future digital therapeutics.

Chronic pain is a transdiagnostic condition which manifests in patients with diverse underlying pathologies such as rheumatoid arthritis, diabetic neuropathy, fibromyalgia, and irritable bowel syndrome. This basket study aims to evaluate the efficacy, safety, and tolerability of CT-100-002 on measures of pain, pain-related functioning, and mood across multiple indications. The study results will further future clinical development of digital therapeutics comprising DiNaMo™ mechanisms of action.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: February 6, 2023
• Est. primary completion date: February 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Meets indication-specific eligibility criteria as reported by the study participant with adequate clinical documentation

• Self-reported average pain intensity during the last 7 days of = 3 of 10 on the Numeric rating Scale (NRS scale) associated with the primary indication

• Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.)

• Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey.

• Lives in the United States.

• Has an active email address and is willing and able to receive email messages.

• Is the sole user of an iPhone with iPhone operating systems (iOS) 14 or later capabilities or a smartphone with an Android operating system (OS) 10 or later capabilities with cellular and/or internet access for the duration of the study period.

Exclusion Criteria:

• Has a comorbid acute pain condition, such as from current injuries

• Participation in a clinical trial (including psychotherapy, mindfulness, cognitive training, or drug treatment) within the last 2 months

• Initiation or change in primary disease-specific medication for 30 days prior to entering the study

• Self-reported substance use disorder within the past 1 year

• Daily use of opioids of 30 MME (Morphine Milligram Equivalents) or more

• Substance use disorder within the past 1 year.

• Initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months.

• Participation in a clinical trial within the last 2 months.

• Planning to introduce new therapies or change therapies during the study duration

• Visual, dexterity or cognitive deficit so severe that precludes the use of an app per investigator judgment.

• Severe psychiatric disorder involving a history of psychosis

• Other significant medical condition that may confound the interpretation of findings

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Diabetic Neuropathy
• Fibromyalgia
• Irritable Bowel Syndrome
• Myofascial Pain Syndromes
• Rheumatoid Arthritis

Intervention

Device:
• DiNaMo Study App
Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
• Placebo App
Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy

Locations

Country	Name	City	State
United States	Click Therapeutics	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Click Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group	Effect size change as measured by the Numerical Rating Scale (NRS) questionnaire, from the lowest (0) to the highest (10)	Change from Baseline to Week 4
Secondary	To explore the feasibility of remote digital DiNaMo training Study App in participants with chronic pain	Feasibility is measured by using User Experience Questionnaire including engagement and experience with the Study App in participants with chronic pain as measured by metrics such as daily app usage and daily time in the app. The questionnaire will ask questions related to the perceived enjoyment, challenges, and related user experience.	User experience questionnaire of feasibility recorded on baseline and Week 4
Secondary	To estimate the effect size for changes in attention to pain in the Treatment App group compared to the Digital Control App group	Change is measured by the Pain Vigilance and Awareness Questionnaire (PVAQ), from the lowest (0) to the highest (5).	Change from baseline to Week 4
Secondary	To estimate the effect size for changes in pain catastrophizing in the Treatment App group compared to the Digital Control App group	Change is measured by the Pain Catastrophizing Scale (PCS) from the lowest (0) to the highest (4).	Change from baseline to Week 4
Secondary	To estimate the effect size for changes in confidence in dealing with chronic pain in the Treatment App group compared to the Digital Control App group	Change is measured by the Pain Self-efficacy Questionnaire (PSEQ) from the lowest (0) to the highest (6).	Change from baseline to Week 4